Omipalisib

DB12703InvestigationalSmall molecule

Omipalisib has been used in trials studying the treatment of CANCER, Solid Tumours, and Idiopathic Pulmonary Fibrosis.

Chemical structure of Omipalisib
Mechanism
Curator reviewed
Formula / weight
C25H17F2N5O3S · 505.496 g/mol (avg)
Code names
GSK2126458

Resolves to

Compound
UNII1X8F5A3NA0CAS1086062-66-9ChEMBLCHEMBL1236962ChEBI95093PubChem25167777
Structure
InChIKeyCGBJSGAELGCMKE-UHFFFAOYSA-NSMILESCOC1=C(NS(=O)(=O)C2=C(F)C=C(F)C=C2)C=C(C=N1)C1=CC2=C(C=CN=C2C=C1)C1=CN=NC=C1
Targets
P42345MTORP48736PIK3CG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Omipalisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In